Aratana Therapeutics (PETX) Upgraded by BidaskClub to Strong-Buy

Aratana Therapeutics (NASDAQ:PETX) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

Other research analysts have also recently issued reports about the company. Stifel Nicolaus reduced their price objective on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, August 6th. Zacks Investment Research upgraded Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research note on Tuesday, September 11th. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a research note on Monday. Finally, ValuEngine upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 22nd. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $8.17.

Aratana Therapeutics stock traded down $0.15 during midday trading on Thursday, reaching $6.82. The company’s stock had a trading volume of 447,543 shares, compared to its average volume of 519,259. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.44 and a current ratio of 3.17. Aratana Therapeutics has a 52-week low of $3.67 and a 52-week high of $7.28. The stock has a market cap of $325.30 million, a PE ratio of -7.03 and a beta of 1.95.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. Aratana Therapeutics had a negative return on equity of 15.08% and a negative net margin of 52.94%. The firm had revenue of $21.56 million during the quarter, compared to analysts’ expectations of $5.70 million. As a group, sell-side analysts predict that Aratana Therapeutics will post -0.35 EPS for the current fiscal year.

In related news, CEO Peter Steven St sold 75,000 shares of the firm’s stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $6.06, for a total transaction of $454,500.00. Following the sale, the chief executive officer now directly owns 574,233 shares of the company’s stock, valued at $3,479,851.98. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Ernst Heinen sold 10,372 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $5.15, for a total value of $53,415.80. Following the sale, the insider now directly owns 157,406 shares in the company, valued at $810,640.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 102,205 shares of company stock valued at $604,026. Company insiders own 5.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. acquired a new stake in Aratana Therapeutics during the second quarter worth about $195,000. Bank of Montreal Can grew its holdings in Aratana Therapeutics by 152.9% during the third quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 31,053 shares during the period. Acadian Asset Management LLC acquired a new stake in Aratana Therapeutics during the second quarter worth about $487,000. Northern Trust Corp grew its holdings in Aratana Therapeutics by 7.2% during the second quarter. Northern Trust Corp now owns 489,766 shares of the biopharmaceutical company’s stock worth $2,082,000 after acquiring an additional 32,773 shares during the period. Finally, Grandeur Peak Global Advisors LLC grew its holdings in Aratana Therapeutics by 29.4% during the second quarter. Grandeur Peak Global Advisors LLC now owns 712,138 shares of the biopharmaceutical company’s stock worth $3,027,000 after acquiring an additional 161,675 shares during the period. 66.22% of the stock is currently owned by hedge funds and other institutional investors.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

See Also: Buyback

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply